Hospital
Riverside Hospital INC
Riverside Hospital INC was paid $136.80M by Medicaid between Jan 2018 and Dec 2024, across 623 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 9.6% of everything it billed.
33Billing provider infoRIVERSIDE HOSPITAL INC
NEWPORT NEWS, VA 23601
NEWPORT NEWS, VA 23601
33aNPI1366547747assigned 09/13/2006
33bProvider typePsychiatric Hospital
28Total paid$136.80M
24GClaims3,118,184
24DCodes billed623
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital providers in Virginia
Rank by total paid#1 of 7
Median peer was paid$1.36M
This provider vs. median101×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official AUSTIN, WALTER controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 239,240 | $7.24M | |
| 2019 | 356,070 | $13.00M | |
| 2020 | 402,729 | $16.71M | |
| 2021 | 499,562 | $19.28M | |
| 2022 | 532,280 | $24.64M | |
| 2023 | 590,204 | $27.65M | |
| 2024incomplete | 498,099 | $28.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.6% | 141,668 | 106,022 | $13.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.9% | 45,888 | 29,953 | $12.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 63,195 | 51,871 | $10.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.2% | 60,205 | 51,602 | $9.83M |
| J9271 | Injection, pembrolizumab, 1 mg | 4.4% | 1,370 | 964 | $6.07M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 112,487 | 34,880 | $5.49M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 24,406 | 21,475 | $3.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 19,678 | 16,189 | $2.77M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 4,237 | 3,934 | $2.63M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 15,160 | 13,319 | $2.63M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.9% | 3,973 | 3,665 | $2.57M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 14,410 | 12,373 | $2.52M |
611 more codes
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.5% | 3,468 | $2.08M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.4% | 12,764 | $1.98M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 6,511 | $1.91M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.4% | 2,239 | $1.89M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 22,345 | $1.84M |
| G0378 | Hospital observation service, per hour | 1.3% | 11,808 | $1.82M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 15,856 | $1.77M |
| 59025 | Fetal non-stress test | 1.2% | 10,137 | $1.67M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 8,615 | $1.51M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 2,609 | $1.49M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,439 | $1.27M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,829 | $1.21M |
| 97161 | <1% | 10,377 | $1.19M | |
| 97162 | <1% | 9,781 | $1.12M | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,922 | $1.08M |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 670 | $1.06M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,646 | $974K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 684 | $963K |
| 96415 | <1% | 4,728 | $890K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 21,299 | $871K |
| 20610 | <1% | 5,010 | $860K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,201 | $801K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 735 | $769K |
| J0897 | Injection, denosumab, 1 mg | <1% | 2,038 | $739K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 828 | $714K |
| 77412 | <1% | 1,319 | $633K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,079 | $600K |
| 76642 | <1% | 4,916 | $598K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 27,680 | $573K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,828 | $572K |
| 29581 | <1% | 2,940 | $554K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 9,824 | $539K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,638 | $520K |
| 93017 | <1% | 4,008 | $462K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15,255 | $459K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,874 | $458K |
| 62323 | <1% | 1,086 | $423K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,348 | $406K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 14,449 | $405K |
| 72141 | <1% | 2,015 | $392K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 5,207 | $383K |
| 97598 | <1% | 1,036 | $379K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,300 | $376K |
| 93971 | <1% | 3,610 | $362K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,597 | $356K |
| 76830 | Ultrasound, transvaginal | <1% | 3,408 | $354K |
| 19083 | <1% | 297 | $350K | |
| 97113 | <1% | 6,852 | $347K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,774 | $333K |
| 97597 | <1% | 4,441 | $323K | |
| 20611 | <1% | 852 | $313K | |
| 76536 | <1% | 2,831 | $311K | |
| 64483 | <1% | 490 | $310K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 388 | $309K |
| 97165 | <1% | 3,880 | $302K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,778 | $295K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 125 | $287K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 5,574 | $284K |
| 58558 | <1% | 180 | $267K | |
| 70498 | <1% | 1,959 | $266K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,112 | $261K |
| 96416 | <1% | 1,703 | $259K | |
| 64615 | <1% | 630 | $248K | |
| 73030 | <1% | 9,981 | $242K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,212 | $236K |
| 80053 | Comprehensive metabolic panel | <1% | 55,618 | $228K |
| 95816 | <1% | 1,036 | $213K | |
| 97163 | <1% | 2,216 | $211K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 66,908 | $210K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 47,160 | $210K |
| 77336 | <1% | 2,681 | $209K | |
| 94060 | <1% | 3,402 | $207K | |
| 95806 | <1% | 603 | $206K | |
| 76775 | <1% | 2,317 | $205K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 790 | $202K |
| 73562 | <1% | 7,247 | $202K | |
| 70496 | <1% | 1,917 | $197K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,316 | $196K |
| 73630 | <1% | 7,897 | $194K | |
| 72100 | <1% | 6,688 | $192K | |
| 43235 | <1% | 351 | $192K | |
| 71250 | <1% | 2,717 | $182K | |
| 52000 | <1% | 234 | $176K | |
| 77373 | <1% | 177 | $174K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,769 | $173K |
| 96367 | <1% | 6,090 | $171K | |
| 97750 | <1% | 4,189 | $165K | |
| 93321 | <1% | 545 | $165K | |
| 73130 | <1% | 6,597 | $164K | |
| 77334 | <1% | 1,828 | $162K | |
| 73610 | <1% | 6,445 | $161K | |
| 73221 | <1% | 775 | $158K | |
| 95886 | <1% | 1,446 | $157K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,478 | $153K |
| 94726 | <1% | 4,549 | $152K | |
| 73560 | <1% | 7,029 | $151K | |
| 64493 | <1% | 179 | $150K | |
| 58661 | <1% | 56 | $150K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,411 | $148K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,329 | $147K |
| 71271 | <1% | 1,340 | $144K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,396 | $143K |
| 93970 | <1% | 1,265 | $143K | |
| 70491 | <1% | 925 | $138K | |
| 36430 | <1% | 964 | $135K | |
| 94729 | <1% | 4,671 | $128K | |
| 72040 | <1% | 3,672 | $127K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 34,691 | $126K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,807 | $125K |
| 77066 | Tomosynthesis, mammo | <1% | 2,853 | $117K |
| 73502 | <1% | 4,996 | $114K | |
| 80047 | <1% | 38,372 | $113K | |
| 43248 | <1% | 185 | $111K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 114,143 | $111K |
| 70486 | <1% | 2,444 | $109K | |
| 77080 | <1% | 1,811 | $107K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,195 | $106K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 44 | $103K |
| 73110 | <1% | 3,973 | $102K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 571 | $101K |
| 77065 | Tomosynthesis, mammo | <1% | 2,473 | $99K |
| 71045 | Radiologic examination, chest; single view | <1% | 30,653 | $97K |
| 74018 | <1% | 4,182 | $94K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31,614 | $93K |
| 74183 | <1% | 267 | $92K | |
| 76882 | <1% | 990 | $92K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 6,251 | $90K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 972 | $88K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 1,342 | $87K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 52 | $87K |
| 72050 | <1% | 2,478 | $86K | |
| 73564 | <1% | 2,956 | $82K | |
| J3490 | Unclassified drugs | <1% | 90,031 | $80K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 553 | $75K |
| 96417 | <1% | 4,451 | $74K | |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | <1% | 35 | $72K |
| 77295 | <1% | 104 | $70K | |
| 72110 | <1% | 2,200 | $70K | |
| 49083 | <1% | 140 | $70K | |
| 97035 | <1% | 1,496 | $70K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,184 | $67K |
| 97164 | <1% | 893 | $66K | |
| 96523 | <1% | 1,312 | $65K | |
| J9306 | Injection, pertuzumab, 1 mg | <1% | 33 | $64K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 155 | $62K |
| 72070 | <1% | 2,181 | $62K | |
| 77290 | <1% | 217 | $61K | |
| 77300 | <1% | 891 | $59K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 360 | $59K |
| 96402 | <1% | 1,853 | $55K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 18,936 | $55K |
| 93325 | <1% | 838 | $54K | |
| 93308 | <1% | 312 | $54K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,995 | $53K |
| 73590 | <1% | 2,839 | $53K | |
| 83880 | <1% | 6,929 | $52K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,746 | $52K |
| 94010 | <1% | 1,292 | $52K | |
| 97802 | <1% | 918 | $52K | |
| 87040 | <1% | 7,791 | $52K | |
| 31575 | <1% | 449 | $50K | |
| 73140 | <1% | 1,913 | $49K | |
| 87510 | <1% | 5,559 | $49K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,339 | $49K |
| 95885 | <1% | 419 | $46K | |
| 92610 | <1% | 699 | $46K | |
| 97116 | <1% | 2,043 | $46K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 508 | $45K |
| 93458 | <1% | 36 | $45K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,900 | $44K |
| 93296 | <1% | 2,970 | $43K | |
| 64616 | <1% | 94 | $43K | |
| 74178 | <1% | 166 | $42K | |
| 84484 | <1% | 42,310 | $41K | |
| 90715 | <1% | 2,553 | $40K | |
| 73552 | <1% | 1,950 | $40K | |
| 76937 | <1% | 1,466 | $39K | |
| 36561 | <1% | 29 | $39K | |
| 80076 | <1% | 15,859 | $38K | |
| 73080 | <1% | 1,627 | $38K | |
| 82947 | <1% | 40,318 | $36K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,117 | $36K |
| 20552 | <1% | 220 | $36K | |
| 73700 | <1% | 470 | $35K | |
| 73620 | <1% | 1,297 | $34K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 816 | $34K |
| 72120 | <1% | 844 | $34K | |
| S0201 | Partial hospitalization services, less than 24 hours, per diem | <1% | 148 | $34K |
| 93880 | <1% | 512 | $33K | |
| 78264 | <1% | 101 | $33K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,262 | $32K |
| 95811 | <1% | 64 | $31K | |
| 72170 | <1% | 2,208 | $30K | |
| 81003 | <1% | 17,035 | $30K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,331 | $30K |
| 93225 | <1% | 550 | $29K | |
| 76942 | <1% | 727 | $29K | |
| 81001 | <1% | 41,543 | $29K | |
| 93922 | <1% | 475 | $29K | |
| 72156 | <1% | 178 | $29K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,316 | $27K |
| 43249 | <1% | 58 | $26K | |
| 88307 | <1% | 2,263 | $26K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 135 | $26K |
| 62321 | <1% | 43 | $26K | |
| 76870 | <1% | 273 | $26K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 44,709 | $26K |
| 87660 | <1% | 5,559 | $25K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,916 | $25K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 29,794 | $25K |
| 29125 | <1% | 184 | $25K | |
| 72158 | <1% | 112 | $24K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 14,145 | $24K |
| 72114 | <1% | 730 | $23K | |
| 96401 | <1% | 1,794 | $23K | |
| 92557 | <1% | 586 | $23K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 43 | $23K |
| C8923 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography | <1% | 103 | $21K |
| 73120 | <1% | 741 | $21K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 5,352 | $20K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 489 | $20K |
| A9150 | Non-prescription drugs | <1% | 194,858 | $20K |
| J2323 | Injection, natalizumab, 1 mg | <1% | 15 | $20K |
| 12011 | <1% | 127 | $20K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 185 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,305 | $20K |
| 77001 | <1% | 385 | $19K | |
| 85379 | <1% | 4,797 | $19K | |
| 84702 | <1% | 7,196 | $19K | |
| 95909 | <1% | 294 | $19K | |
| 12002 | <1% | 123 | $18K | |
| 85610 | <1% | 16,854 | $18K | |
| 73521 | <1% | 696 | $18K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 38,810 | $18K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 575 | $18K |
| 84145 | <1% | 2,487 | $18K | |
| 86885 | <1% | 8,971 | $17K | |
| 95911 | <1% | 246 | $17K | |
| 73600 | <1% | 1,008 | $16K | |
| 12001 | <1% | 94 | $16K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 190 | $16K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 905 | $16K |
| 93226 | <1% | 291 | $16K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 121 | $15K |
| 80061 | Lipid panel | <1% | 5,418 | $15K |
| 80069 | <1% | 5,542 | $15K | |
| J2704 | Injection, propofol, 10 mg | <1% | 47,868 | $15K |
| 73090 | <1% | 1,107 | $15K | |
| 83605 | <1% | 15,190 | $14K | |
| 51798 | <1% | 2,452 | $14K | |
| 69210 | <1% | 225 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 11,338 | $14K |
| 93242 | <1% | 223 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,263 | $13K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 706 | $13K |
| 97166 | <1% | 142 | $13K | |
| 86140 | <1% | 6,183 | $12K | |
| Q3014 | Telehealth originating site facility fee | <1% | 880 | $12K |
| 97012 | <1% | 470 | $12K | |
| 20550 | <1% | 52 | $12K | |
| 83970 | <1% | 1,002 | $11K | |
| 73565 | <1% | 905 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,764 | $11K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,113 | $11K |
| 81025 | <1% | 17,172 | $11K | |
| 85014 | <1% | 40,208 | $10K | |
| 64494 | <1% | 115 | $10K | |
| 88304 | <1% | 1,766 | $10K | |
| 95874 | <1% | 206 | $10K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 119 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,183 | $10K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 462 | $10K |
| 86900 | <1% | 10,576 | $10K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 214 | $9K |
| 72131 | <1% | 249 | $9K | |
| 74174 | <1% | 56 | $9K | |
| 84439 | <1% | 4,496 | $9K | |
| 83735 | <1% | 25,484 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,031 | $9K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 118 | $9K |
| 82728 | <1% | 4,775 | $8K | |
| 86923 | <1% | 482 | $8K | |
| 87522 | Neg quan hep c or qual rna | <1% | 424 | $8K |
| 10060 | <1% | 115 | $8K | |
| 93298 | <1% | 339 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,716 | $8K |
| 73060 | <1% | 533 | $8K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 103 | $8K |
| 86235 | <1% | 1,858 | $8K | |
| C1769 | Guide wire | <1% | 4,416 | $7K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 39 | $7K |
| 76604 | <1% | 99 | $7K | |
| 94660 | <1% | 34 | $7K | |
| 80177 | <1% | 1,821 | $7K | |
| 73522 | <1% | 223 | $7K | |
| 82607 | <1% | 3,158 | $7K | |
| 99223 | Prolong inpt eval add15 m | <1% | 78 | $7K |
| 64450 | <1% | 51 | $7K | |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 3,108 | $6K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 112 | $6K |
| 51702 | <1% | 502 | $6K | |
| 93923 | <1% | 80 | $6K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 62 | $6K |
| 93270 | <1% | 127 | $6K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,767 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 48 | $6K |
| 97760 | <1% | 159 | $6K | |
| 85652 | <1% | 5,212 | $6K | |
| 86901 | <1% | 10,576 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 31,390 | $6K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 960 | $6K |
| 88342 | <1% | 3,343 | $6K | |
| 95819 | <1% | 28 | $6K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 25 | $6K |
| 99152 | <1% | 5,516 | $6K | |
| 86038 | <1% | 1,277 | $6K | |
| 90686 | <1% | 424 | $5K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 3,586 | $5K |
| 74220 | <1% | 47 | $5K | |
| 84112 | <1% | 873 | $5K | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 34 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,032 | $5K |
| 94618 | <1% | 66 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 23,072 | $5K |
| 88341 | <1% | 1,725 | $5K | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 873 | $5K |
| 83550 | <1% | 4,738 | $5K | |
| 20553 | <1% | 24 | $5K | |
| 82565 | <1% | 3,872 | $5K | |
| 96411 | <1% | 2,080 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,017 | $4K |
| 82803 | <1% | 8,968 | $4K | |
| 77399 | <1% | 82 | $4K | |
| 86756 | <1% | 740 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,852 | $4K |
| 87340 | <1% | 1,760 | $4K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 63 | $4K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 93 | $4K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 97 | $4K |
| 82570 | <1% | 3,455 | $4K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 60 | $4K |
| 76801 | <1% | 35 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,643 | $4K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 67 | $4K |
| 92567 | <1% | 380 | $4K | |
| 85027 | <1% | 2,751 | $4K | |
| 74022 | <1% | 575 | $4K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 59 | $4K |
| 77002 | <1% | 30 | $4K | |
| 87077 | <1% | 7,108 | $4K | |
| 83540 | <1% | 4,828 | $4K | |
| 80143 | <1% | 892 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26,224 | $3K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,911 | $3K |
| 96376 | <1% | 13,619 | $3K | |
| 73070 | <1% | 199 | $3K | |
| 96377 | <1% | 655 | $3K | |
| 95910 | <1% | 48 | $3K | |
| 83690 | <1% | 21,901 | $3K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 2,909 | $3K |
| 87070 | <1% | 2,608 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,907 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 345 | $3K |
| 96368 | <1% | 3,280 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,988 | $3K |
| 84703 | <1% | 11,232 | $3K | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 1,801 | $3K |
| 78306 | <1% | 12 | $3K | |
| 86920 | <1% | 2,079 | $3K | |
| 86592 | <1% | 1,710 | $3K | |
| 80164 | <1% | 743 | $3K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 3,942 | $3K |
| 88185 | <1% | 244 | $3K | |
| 90677 | <1% | 43 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 16,259 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,443 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,809 | $2K |
| 84550 | <1% | 2,763 | $2K | |
| 73100 | <1% | 124 | $2K | |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 13 | $2K |
| 85018 | <1% | 2,922 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,439 | $2K |
| 87186 | <1% | 6,192 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 3,476 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 7,911 | $2K |
| 87081 | <1% | 4,298 | $2K | |
| 51784 | <1% | 26 | $2K | |
| 86803 | <1% | 444 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,750 | $2K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 1,024 | $2K |
| 76770 | <1% | 14 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 57 | $2K |
| 84100 | <1% | 4,001 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,308 | $2K |
| 80179 | <1% | 770 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,960 | $2K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 36 | $2K |
| 76981 | <1% | 21 | $2K | |
| 85730 | <1% | 5,004 | $2K | |
| 82077 | <1% | 6,086 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 232 | $2K |
| 87480 | <1% | 5,452 | $2K | |
| 76999 | <1% | 14 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 177 | $2K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 202 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,556 | $1K |
| 87205 | <1% | 2,952 | $1K | |
| 93297 | <1% | 118 | $1K | |
| 82550 | <1% | 3,238 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 519 | $1K |
| 86225 | <1% | 645 | $1K | |
| 72190 | <1% | 32 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 7,502 | $1K |
| 88112 | <1% | 141 | $1K | |
| 86431 | <1% | 413 | $1K | |
| 90661 | <1% | 55 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 8,692 | $1K |
| 17250 | <1% | 14 | $1K | |
| 82105 | <1% | 125 | $1K | |
| 84153 | <1% | 599 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,579 | $1K |
| 87430 | <1% | 3,770 | $1K | |
| 83615 | <1% | 2,353 | $1K | |
| 84156 | <1% | 2,279 | $1K | |
| 82746 | <1% | 988 | $1K | |
| 82784 | <1% | 689 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,502 | $1K |
| 82043 | <1% | 658 | $1K | |
| 87902 | <1% | 85 | $999.73 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,768 | $996.30 |
| 84403 | <1% | 139 | $993.42 | |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | <1% | 25 | $990.72 |
| 64405 | <1% | 14 | $985.19 | |
| 95908 | <1% | 13 | $929.72 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,763 | $905.63 |
| 36592 | <1% | 1,451 | $842.52 | |
| 83883 | <1% | 63 | $812.36 | |
| 95913 | <1% | 13 | $810.67 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,055 | $804.51 |
| 89060 | <1% | 812 | $790.76 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 649 | $783.71 |
| 84132 | <1% | 1,124 | $761.31 | |
| 86704 | <1% | 189 | $755.44 | |
| 82248 | <1% | 1,425 | $710.97 | |
| 86706 | <1% | 251 | $663.26 | |
| 72128 | <1% | 30 | $648.30 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,645 | $646.80 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,385 | $645.13 |
| 82533 | <1% | 379 | $641.03 | |
| 36000 | <1% | 303 | $626.60 | |
| 00811 | <1% | 2,477 | $623.97 | |
| 00840 | <1% | 1,174 | $623.65 | |
| 88173 | <1% | 591 | $615.69 | |
| 84481 | <1% | 188 | $603.15 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,095 | $598.48 |
| 82378 | <1% | 293 | $581.84 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,060 | $568.11 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 287 | $532.32 |
| 81002 | <1% | 2,983 | $488.03 | |
| 73000 | <1% | 14 | $473.40 | |
| 84480 | <1% | 375 | $464.36 | |
| 86709 | <1% | 144 | $436.14 | |
| 00731 | <1% | 4,003 | $418.75 | |
| 83010 | <1% | 75 | $412.59 | |
| 88360 | <1% | 66 | $405.44 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,033 | $402.71 |
| 80305 | <1% | 408 | $399.91 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 26 | $395.68 |
| 82140 | <1% | 739 | $382.55 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 309 | $375.26 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,515 | $370.76 |
| 88313 | <1% | 288 | $358.75 | |
| 87116 | <1% | 16 | $337.95 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,632 | $318.34 |
| 80323 | <1% | 14 | $288.70 | |
| 82330 | <1% | 449 | $272.50 | |
| 82172 | <1% | 60 | $271.87 | |
| 82977 | <1% | 107 | $270.55 | |
| 82553 | <1% | 72 | $259.50 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 386 | $257.43 |
| 36600 | <1% | 94 | $256.83 | |
| 88184 | <1% | 14 | $250.26 | |
| 86364 | <1% | 55 | $229.04 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,517 | $228.45 |
| 85045 | <1% | 995 | $228.11 | |
| 83516 | <1% | 92 | $228.05 | |
| 00812 | <1% | 2,995 | $212.60 | |
| 86708 | <1% | 73 | $212.00 | |
| 00910 | <1% | 29 | $200.17 | |
| 71101 | <1% | 16 | $190.59 | |
| 93350 | <1% | 107 | $178.83 | |
| 86870 | <1% | 14 | $162.14 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 25 | $160.82 |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 1,365 | $157.95 |
| A9270 | Non-covered item or service | <1% | 23,619 | $148.84 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,091 | $146.51 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 11,443 | $135.91 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 740 | $132.66 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 795 | $115.93 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 99 | $115.68 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 787 | $109.94 |
| 86300 | <1% | 264 | $102.51 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,589 | $87.76 |
| 00940 | <1% | 61 | $85.77 | |
| 82010 | <1% | 683 | $80.92 | |
| 83993 | <1% | 12 | $77.52 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,183 | $69.37 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,040 | $65.89 |
| 86200 | <1% | 14 | $65.70 | |
| 84165 | <1% | 13 | $57.28 | |
| 87206 | <1% | 138 | $56.04 | |
| 82040 | <1% | 15 | $55.83 | |
| 01480 | <1% | 93 | $54.38 | |
| 82247 | <1% | 15 | $43.03 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,857 | $41.97 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,119 | $41.58 |
| 00400 | <1% | 334 | $41.32 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 127 | $39.22 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 655 | $38.24 |
| A4312 | Insertion tray without drainage bag with indwelling catheter, foley type, two-way, all silicone | <1% | 156 | $36.38 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 280 | $33.55 |
| 84155 | <1% | 30 | $32.83 | |
| A6220 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 430 | $32.24 |
| 87653 | <1% | 28 | $30.50 | |
| 00952 | <1% | 463 | $29.79 | |
| 00300 | <1% | 103 | $29.62 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 340 | $28.92 |
| 00142 | <1% | 2,152 | $26.83 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 579 | $26.71 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 342 | $25.35 |
| 84295 | <1% | 515 | $24.02 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 442 | $23.15 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 850 | $20.41 |
| 86308 | <1% | 14 | $12.96 | |
| 87075 | <1% | 80 | $12.75 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 47 | $8.53 |
| 87102 | <1% | 31 | $8.50 | |
| 87015 | <1% | 16 | $8.50 | |
| 85384 | <1% | 49 | $6.41 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 641 | $4.90 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 49 | $4.44 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 100 | $3.39 |
| 88300 | <1% | 77 | $3.01 | |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 30 | $2.30 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 672 | $2.18 |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 306 | $0.67 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 594 | $0.23 |
| A4320 | Irrigation tray with bulb or piston syringe, any purpose | <1% | 190 | $0.21 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 556 | $0.14 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 132 | $0.13 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 109 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 78 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 225 | $0.00 |
| 01810 | 0% | 30 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 101 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 105 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 44 | $0.00 |
| 89051 | 0% | 16 | $0.00 | |
| A4327 | Female external urinary collection device; meatal cup, each | 0% | 445 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 621 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 343 | $0.00 |
| 88302 | 0% | 57 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 1,206 | $0.00 |
| S9474 | Enterostomal therapy by a registered nurse certified in enterostomal therapy, per diem | 0% | 29 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 651 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 192 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 46 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 108 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 104 | $0.00 |
| V2630 | Anterior chamber intraocular lens | 0% | 33 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 217 | $0.00 |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 53 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 30 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 80 | $0.00 |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | 0% | 38 | $0.00 |
| 94664 | 0% | 17 | $0.00 | |
| 96549 | 0% | 12 | $0.00 | |
| A4357 | Bedside drainage bag, day or night, with or without anti-reflux device, with or without tube, each | 0% | 20 | $0.00 |
| A4565 | Slings | 0% | 13 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 13 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 741 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 1,006 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 26 | $0.00 |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 103 | $0.00 |
| A6549 | Gradient compression garment, not otherwise specified, for daytime use, each | 0% | 304 | $0.00 |
| 94761 | 0% | 417 | $0.00 | |
| 00813 | 0% | 278 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 24 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 1,663 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 106 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 306 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 496 | $0.00 |
| 00790 | 0% | 73 | $0.00 | |
| 00902 | 0% | 40 | $0.00 | |
| 99417 | Prolong home eval add 15m | 0% | 221 | $0.00 |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 0% | 17 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 223 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 28 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 37 | $0.00 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | 0% | 17 | $0.00 |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | 0% | 16 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 899 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 20 | $0.00 |
| 51797 | 0% | 26 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 81 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 118 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 45 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 36 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 24 | $0.00 |
| 88311 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAUSTIN, WALTER (CFO)
| Provider | Location | Paid |
|---|---|---|
| Shore Health Services INC. | Onancock, VA | $24.72M |
| Riverside Middle Peninsula Hospital INC | Gloucester, VA | $19.02M |
| Doctors' Hospital of Williamsburg | Williamsburg, VA | $11.99M |
| Riverside Hospital INC | Newport News, VA | $4.48M |
| Patrick Henry Hospital, INC. | Newport News, VA | $1.52M |
| Shore Health Services, INC | Accomac, VA | $1.31M |
| Riverside Hospice and Homecare Services LLC | Warsaw, VA | $438K |
| Riverside Hospital INC | Newport News, VA | $412K |
| Riverside Middle Peninsula Hospital INC | Gloucester, VA | $37K |
| Riverside Hospital, INC | Newport News, VA | $6K |
| Patrick Henry Hospital, INC. | West Point, VA | $4K |
| Shore Health Services INC | Accomac, VA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.